Business
Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025
Conference call today, March 31, 2025 at 4:30 PM ETSAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2024 and revenue outlook for 2025. “2024 has been an important year for Bionano. Despite a challenging external environment with shrinking capital budgets, financial uncertainty for our customers and difficult equity capital markets, we have continued serving our mission of t
About this update from Bionano Genomics, Inc.
[{"type":"image","alt":"Bionano Genomics","displaySize":"","headline":null,"caption":"Bionano Genomics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":61,"url":"https://media.zenfs.com/en/globenewswire.com/b39fec01655bcf34db9e215be03042b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ylN8_Gs3_qAPxed5dOQIGw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b39fec01655bcf34db9e215be03042b1","width":300,"height":61}},"lazy":false},{"type":"text","content":"Conference call today, March 31, 2025 at 4:30 PM ET","length":51,"tagName":"p"},{"type":"text","content":"SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2024 and revenue outlook for 2025.","length":207,"tagName":"p"},{"type":"text","content":"“2024 has been an important year for Bionano. Despite a challenging external environment with shrinking capital budgets, financial uncertainty for our customers and difficult equity capital markets, we have continued serving our mission of transforming the way the world sees the genome and we believe we have identified a strategy to weather the storm. It is based on substantially lower operating expenses and a focus on the subset of optical genome mapping (OGM) and software customers that are using our products for routine use in a way that drives consistent and recurring revenues supporting higher overall gross profits. I could not be more proud of our team as the fourth quarter of 2024 marks the seventh straight quarter of heavy lifting on the cost reduction efforts that began in May 2023. Altogether we have reduced the annualized cost of operating the business by approximately $100 million,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.","length":991,"tagName":"p"},{"type":"text","content":"“We concluded the year with a lot of momentum, solid revenues from OGM and VIA™ software across priority customers and target geographies. We entered 2025 with strong demand for our products and the newly established category I CPT code for OGM on the clinical lab fee schedule managed by the Centers for Medicaid and Medicare Services (CMS) and we believe we have cash runway into 2026.”","length":388,"tagName":"p"},{"type":"text"...